.png)
Eli Lilly and Company reports strong Phase 3 data for Ebglyss, showing major skin improvement and itch relief in children with moderate-to-severe atopic dermatitis.
Piramal Pharma Solutions has completed its 1,500th ADC batch at its facility in Grangemouth, marking a key milestone in the company’s global ADC development and manufacturing journey.
Abbott launches the ICRAS Tool in India to help doctors detect heart and kidney risks early in people with type 2 diabetes, supporting better cardio-renal risk assessment and patient outcomes.
BPL Medical Technologies has launched advanced bone mineral density diagnostic systems in India and Dubai after acquiring YozmaBMtech, expanding its capabilities in osteoporosis screening, imaging technology, and preventive healthcare.
Pfizer reported encouraging Phase 2 results for tilrekimig, a trispecific antibody for moderate to severe atopic dermatitis. The drug improved EASI-75 response rates and showed strong efficacy with monthly dosing.
Merck and Cyto-Facto sign an MoU to accelerate cell and gene therapy manufacturing in APAC, focusing on Japan and India, with a goal to improve patient access to therapies.
Agilent signs $950 million deal to acquire Biocare Medical, enhancing its cancer diagnostics and pathology portfolio with innovative IHC and molecular pathology solutions.
Bristol Myers Squibb reported positive results from a late-stage trial of its experimental drug mezigdomide for multiple myeloma, showing improved progression-free survival in patients whose cancer returned or resisted prior treatment.
Lonza sells its Capsules & Health Ingredients unit for CHF 2.3B to Lone Star Funds, completing its shift to a pure-play CDMO. Proceeds will fuel growth, acquisitions, and share buybacks.
Novo Nordisk is gaining momentum in India’s obesity drug market as semaglutide sales rise following price cuts and wider availability. The move is helping the company narrow the lead held by Eli Lilly’s tirzepatide in the fast-growing GLP-1 segment.
, CDSCO.jpg)